Opicapone for the treatment of Parkinson's disease an update /
Introduction: Parkinson's disease is a neurodegenerative disorder which is characterized by the combination of motor and non-motor symptoms. As yet, there is no curative treatment. The gold standard for symptom control is levodopa. Two years after the start of substitution therapy, around 50% o...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2019
|
| Sorozat: | EXPERT OPINION ON PHARMACOTHERAPY
20 No. 18 |
| doi: | 10.1080/14656566.2019.1681971 |
| mtmt: | 30942814 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/17657 |
| LEADER | 02255nab a2200253 i 4500 | ||
|---|---|---|---|
| 001 | publ17657 | ||
| 005 | 20200514110117.0 | ||
| 008 | 191218s2019 hu o 0|| zxx d | ||
| 022 | |a 1465-6566 | ||
| 024 | 7 | |a 10.1080/14656566.2019.1681971 |2 doi | |
| 024 | 7 | |a 30942814 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Salamon András | |
| 245 | 1 | 0 | |a Opicapone for the treatment of Parkinson's disease |h [elektronikus dokumentum] : |b an update / |c Salamon András |
| 260 | |c 2019 | ||
| 300 | |a 2201-2207 | ||
| 490 | 0 | |a EXPERT OPINION ON PHARMACOTHERAPY |v 20 No. 18 | |
| 520 | 3 | |a Introduction: Parkinson's disease is a neurodegenerative disorder which is characterized by the combination of motor and non-motor symptoms. As yet, there is no curative treatment. The gold standard for symptom control is levodopa. Two years after the start of substitution therapy, around 50% of patients experience some degree of fluctuation in motor performance. Catechol-O-methyltransferase (COMT) inhibitors are important agents in treating these fluctuations.Areas covered: This article summarizes our knowledge about a new third-generation COMT inhibitor, namely opicapone (OPC) (Search period: 2016-2019). The authors detail the pharmacological profile of OPC and summarize the results of completed clinical trials. In addition, they briefly summarize the achievements of the past few years.Expert opinion: Based on clinical trials conducted so far, OPC is an effective and safe new drug. In comparison to entacapone and tolcapone, it does not require close laboratory monitoring or multiple oral administrations, which may result in better adherence. No serious adverse event was reported during the drug development phases. Dyskinesia was the most common complaint. Further comparative studies and broader trial inclusion criteria are needed to help the decision between COMT inhibitors and to expand the patient spectrum where this drug can be applied. | |
| 700 | 0 | 1 | |a Zádori Dénes |e aut |
| 700 | 0 | 1 | |a Szpisjak László |e aut |
| 700 | 0 | 1 | |a Klivényi Péter |e aut |
| 700 | 0 | 1 | |a Vécsei László |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/17657/1/SalamonA._OpicaponeforthetreatmentofParkinsonsdiseaseanupdate.pdf |z Dokumentum-elérés |